Biomarin's hemophilia drug meets all endpoints in phase III study
Biomarin has released results from a phase III trial of gene therapy valoctocogene roxaparvovec against severe hemophilia A.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
On Sunday, Biotech company Biomarin publicized results from the largest study of a gene therapy hemophilia A treatment ever, at least according to the company itself.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
